Illumina Inc.

# Signal Note: Casdin Capital Initiates $78.7M Illumina Position Casdin's entry into ILMN at ~$131/share suggests conviction in sequencing-as-infrastructure demand, likely driven by accelerating clinical genomics adoption and AI-enabled data analysis workflows. This move aligns with Casdin's genomics tools thesis and may signal confidence in ILMN's near-term margin expansion or market share gains in oncology/reproductive health testing where sequencing penetration remains sub-saturated.